Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes
Autor: | Hoi Lam Ngan, Yibing Peng, Chun Kit Yeung, Benjamin Xiaoyi Li, Yukai He, Vivian Wai Yan Lui, Peony Hiu Yan Poon, Yuchen Liu, Helen Hoi Yin Chan, WY Lam, Hui Li |
---|---|
Rok vydání: | 2020 |
Předmět: |
utility analyses
0301 basic medicine Cancer Research whole-exome sequencing analysis AT-84 medicine.medical_treatment 5 immunocompetent metastatic HNC models medicine.disease_cause lcsh:RC254-282 Article Metastasis 03 medical and health sciences 0302 clinical medicine Fanconi anemia medicine Epigenetics Exome business.industry Head and neck cancer Cancer Immunotherapy SCC VII lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research KRAS business |
Zdroj: | Cancers, Vol 12, Iss 2935, p 2935 (2020) Cancers Volume 12 Issue 10 |
ISSN: | 2072-6694 |
Popis: | Immunocompetent metastatic head and neck cancer (HNC) models, although scarce, can help understanding cancer progression and therapy responses in vivo. Their comprehensive genome characterizations are essential for translational research. We first exome-sequenced the two most widely used spontaneous metastatic immunocompetent models, namely AT-84 and SCC VII, followed by comprehensive genomic analyses with three prior-sequenced models (MOC2, MOC2-10, and 4MOSC2), together with patient tumors for utility assessment. AT-84 and SCC VII bear high HNC tumor resemblance regarding mutational signatures&mdash Trp53, Fanconi anemia, and MAPK and PI3K pathway defects. Collectively, the five models harbor genetic aberrations across 10 cancer hallmarks and 14 signaling pathways and machineries (metabolic, epigenetic, immune evasion), to extents similar in patients. Immune defects in HLA-A (H2-Q10, H2-Q4, H2-Q7, and H2-K1), Pdcd1, Tgfb1, Il2ra, Il12a, Cd40, and Tnfrsf14 are identified. Invasion/metastatic genome analyses first highlight potential druggable ERBB4 and KRAS mutations, for advanced/metastatic oral cavity cancer, as well as known metastasis players (Muc5ac, Trem3, Trp53, and Ttn) frequently captured by all models. Notable immunotherapy and precision druggable targets (Pdcd1, Erbb4, Fgfr1, H/Kras, Jak1, and Map2k2) and three druggable hubs (RTK family, MAPK, and DNA repair pathways) are frequently represented by these models. Immunocompetent metastatic HNC models are worth developing to address therapy- and invasion/metastasis-related questions in host immunity contexts. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |